These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 23314736)

  • 21. Polymorphisms in p53, GSTP1 and XRCC1 predict relapse and survival of gastric cancer patients treated with oxaliplatin-based adjuvant chemotherapy.
    Huang ZH; Hua D; Du X
    Cancer Chemother Pharmacol; 2009 Oct; 64(5):1001-7. PubMed ID: 19247656
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Neurotoxicity of FOLFOX-4 as adjuvant treatment for patients with colon and gastric cancer: a randomized study of two different schedules of oxaliplatin.
    Petrioli R; Pascucci A; Francini E; Marsili S; Sciandivasci A; Tassi R; Civitelli S; Tanzini G; Lorenzi M; Francini G
    Cancer Chemother Pharmacol; 2008 Jan; 61(1):105-11. PubMed ID: 17429632
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Predictive value of ERCC1, ERCC2, and XRCC1 overexpression for stage III colorectal cancer patients receiving FOLFOX-4 adjuvant chemotherapy.
    Huang MY; Tsai HL; Lin CH; Huang CW; Ma CJ; Huang CM; Chai CY; Wang JY
    J Surg Oncol; 2013 Dec; 108(7):457-64. PubMed ID: 23996617
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A phase II trial of modified FOLFOX as first-line chemotherapy in advanced colorectal cancer.
    Xiong JP; Zhang L; Zhong LX; Qiu F; Xu J; Tao QS; Xiang XJ; Yu F; Tang XM
    Anticancer Drugs; 2007 Oct; 18(9):1103-7. PubMed ID: 17704661
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer.
    André T; Boni C; Mounedji-Boudiaf L; Navarro M; Tabernero J; Hickish T; Topham C; Zaninelli M; Clingan P; Bridgewater J; Tabah-Fisch I; de Gramont A;
    N Engl J Med; 2004 Jun; 350(23):2343-51. PubMed ID: 15175436
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The toxicity and efficacy of Nordic-FLOX regimen as adjuvant treatment of stage III colon cancer.
    Demir L; Somali I; Oktay Tarhan M; Erten C; Ellidokuz H; Can A; Dirican A; Vedat Bayoglu I
    J BUON; 2011; 16(4):682-8. PubMed ID: 22331722
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Is oxaliplatin combined with weekly bolus 5-fluorouracil and leucovorin an option for stage II and III colon cancer?
    Twelves C
    Nat Clin Pract Oncol; 2008 Feb; 5(2):72-3. PubMed ID: 18030299
    [No Abstract]   [Full Text] [Related]  

  • 28. A meta-analysis of chemotherapy regimen fluorouracil/leucovorin/oxaliplatin compared with fluorouracil/leucovorin in treating advanced colorectal cancer.
    Chen ML; Fang CH; Liang LS; Dai LH; Wang XK
    Surg Oncol; 2010 Mar; 19(1):38-45. PubMed ID: 19345093
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Treatment of advanced gastric cancer with oxaliplatin plus 5-fluorouracil/ leucovorin (FOLFOX-4 chemotherapy)].
    Garrido M; Melgoza G; Galindo H; Madrid J; Sánchez C; Nervi B; Alvarez M; Orellana E
    Rev Med Chil; 2007 Nov; 135(11):1380-7. PubMed ID: 18259648
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacogenetic predictors of outcome in patients with stage II and III colon cancer treated with oxaliplatin and fluoropyrimidine-based adjuvant chemotherapy.
    Custodio A; Moreno-Rubio J; Aparicio J; Gallego-Plazas J; Yaya R; Maurel J; Rodríguez-Salas N; Burgos E; Ramos D; Calatrava A; Andrada E; Díaz-López E; Sánchez A; Madero R; Cejas P; Feliu J
    Mol Cancer Ther; 2014 Sep; 13(9):2226-37. PubMed ID: 24980946
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A Phase II study of oxaliplatin with low-dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFOX-4) for gastric cancer patients with malignant ascites.
    Oh SY; Kwon HC; Lee S; Lee DM; Yoo HS; Kim SH; Jang JS; Kim MC; Jeong JS; Kim HJ
    Jpn J Clin Oncol; 2007 Dec; 37(12):930-5. PubMed ID: 18211984
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer.
    Cassidy J; Clarke S; Díaz-Rubio E; Scheithauer W; Figer A; Wong R; Koski S; Lichinitser M; Yang TS; Rivera F; Couture F; Sirzén F; Saltz L
    J Clin Oncol; 2008 Apr; 26(12):2006-12. PubMed ID: 18421053
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Predictive marker for the efficacy of FOLFOX treatment in colon cancer (TS, ERCC1 etc)].
    Kumamoto K; Ishibashi K; Ishida H
    Nihon Rinsho; 2011 Apr; 69 Suppl 3():494-9. PubMed ID: 22214010
    [No Abstract]   [Full Text] [Related]  

  • 34. Pharmacogenetic approach for capecitabine or 5-fluorouracil selection to be combined with oxaliplatin as first-line chemotherapy in advanced colorectal cancer.
    Martinez-Balibrea E; Abad A; Aranda E; Sastre J; Manzano JL; Díaz-Rubio E; Gómez-España A; Aparicio J; García T; Maestu I; Martínez-Cardús A; Ginés A; Guino E;
    Eur J Cancer; 2008 Jun; 44(9):1229-37. PubMed ID: 18448328
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Influence of chemotherapeutic drug-related gene polymorphisms on toxicity and survival of early breast cancer patients receiving adjuvant chemotherapy.
    Ludovini V; Antognelli C; Rulli A; Foglietta J; Pistola L; Eliana R; Floriani I; Nocentini G; Tofanetti FR; Piattoni S; Minenza E; Talesa VN; Sidoni A; Tonato M; Crinò L; Gori S
    BMC Cancer; 2017 Jul; 17(1):502. PubMed ID: 28747156
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The combination of ERCC1 and XRCC1 gene polymorphisms better predicts clinical outcome to oxaliplatin-based chemotherapy in metastatic colorectal cancer.
    Liang J; Jiang T; Yao RY; Liu ZM; Lv HY; Qi WW
    Cancer Chemother Pharmacol; 2010 Aug; 66(3):493-500. PubMed ID: 19960344
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Genetic polymorphisms affecting clinical outcomes in epithelial ovarian cancer patients treated with taxanes and platinum compounds: a Korean population-based study.
    Kim HS; Kim MK; Chung HH; Kim JW; Park NH; Song YS; Kang SB
    Gynecol Oncol; 2009 May; 113(2):264-9. PubMed ID: 19203783
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Australian experience of a modified schedule of FOLFOX with high activity and tolerability and improved convenience in untreated metastatic colorectal cancer patients.
    Goldstein D; Mitchell P; Michael M; Beale P; Friedlander M; Zalcberg J; White S; Clarke S
    Br J Cancer; 2005 Mar; 92(5):832-7. PubMed ID: 15756253
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: a planned safety analysis in 1,864 patients.
    Schmoll HJ; Cartwright T; Tabernero J; Nowacki MP; Figer A; Maroun J; Price T; Lim R; Van Cutsem E; Park YS; McKendrick J; Topham C; Soler-Gonzalez G; de Braud F; Hill M; Sirzén F; Haller DG
    J Clin Oncol; 2007 Jan; 25(1):102-9. PubMed ID: 17194911
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Neurotoxicity from oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: NSABP C-07.
    Land SR; Kopec JA; Cecchini RS; Ganz PA; Wieand HS; Colangelo LH; Murphy K; Kuebler JP; Seay TE; Needles BM; Bearden JD; Colman LK; Lanier KS; Pajon ER; Cella D; Smith RE; O'Connell MJ; Costantino JP; Wolmark N
    J Clin Oncol; 2007 Jun; 25(16):2205-11. PubMed ID: 17470850
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.